Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$69.32
-2.5%
$65.27
$23.65
$77.00
$6.27B0.221.16 million shs368,759 shs
Insmed, Inc. stock logo
INSM
Insmed
$106.92
-0.5%
$105.20
$90.39
$212.75
$23.28B0.782.50 million shs1.90 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.07
-5.2%
$58.52
$22.28
$85.60
$22.62B0.947.48 million shs4.42 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$35.01
-0.3%
$32.24
$10.90
$37.00
$25.25B1.115.00 million shs4.04 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-2.53%-3.52%+0.87%+0.93%+163.37%
Insmed, Inc. stock logo
INSM
Insmed
-0.46%-1.29%+3.36%-20.90%+3.36%
Moderna, Inc. stock logo
MRNA
Moderna
-5.17%-12.54%-10.51%+6.58%+55.96%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.26%+1.45%+2.94%+27.73%+207.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$69.32
-2.5%
$65.27
$23.65
$77.00
$6.27B0.221.16 million shs368,759 shs
Insmed, Inc. stock logo
INSM
Insmed
$106.92
-0.5%
$105.20
$90.39
$212.75
$23.28B0.782.50 million shs1.90 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.07
-5.2%
$58.52
$22.28
$85.60
$22.62B0.947.48 million shs4.42 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$35.01
-0.3%
$32.24
$10.90
$37.00
$25.25B1.115.00 million shs4.04 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-2.53%-3.52%+0.87%+0.93%+163.37%
Insmed, Inc. stock logo
INSM
Insmed
-0.46%-1.29%+3.36%-20.90%+3.36%
Moderna, Inc. stock logo
MRNA
Moderna
-5.17%-12.54%-10.51%+6.58%+55.96%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-0.26%+1.45%+2.94%+27.73%+207.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$81.7317.90% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$209.1395.60% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.82
Reduce$40.00-26.02% Downside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.59-4.05% Downside

Current Analyst Ratings Breakdown

Latest CGON, ROIV, MRNA, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$49.00 ➝ $67.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Initiated CoverageOutperform$192.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$220.00
7/20/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingUnderperform$25.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
UpgradeStrong-Buy
7/17/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Reiterated RatingSell (D-)
7/17/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingSell (D-)
7/15/2026
Insmed, Inc. stock logo
INSM
Insmed
Boost Price TargetOverweight$160.00 ➝ $161.00
7/10/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$207.00
7/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$33.00 ➝ $39.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$38.00 ➝ $45.00
(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$5.07M1,205.71N/AN/A$9.33 per share7.43
Insmed, Inc. stock logo
INSM
Insmed
$606.42M38.22N/AN/A$3.46 per share30.90
Moderna, Inc. stock logo
MRNA
Moderna
$2.20B9.73N/AN/A$22.14 per share2.44
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,048.63N/AN/A$7.35 per share4.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$5.75N/A181.22N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/6/2026 (Estimated)

Latest CGON, ROIV, MRNA, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.70N/AN/AN/A$0.36 millionN/A
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.69N/AN/AN/A$393.40 millionN/A
8/6/2026Q1 2027
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.33N/AN/AN/A$2.00 millionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.00N/AN/AN/A$103.07 millionN/A
5/8/2026Q1 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million
5/7/2026Q1 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
31.30
31.25
Insmed, Inc. stock logo
INSM
Insmed
0.80
4.47
4.10
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.20 million83.97 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664216.75 million212.20 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CG Oncology stock logo

CG Oncology NASDAQ:CGON

$69.32 -1.80 (-2.53%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$69.26 -0.06 (-0.09%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Insmed stock logo

Insmed NASDAQ:INSM

$106.92 -0.49 (-0.46%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$106.05 -0.87 (-0.81%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna stock logo

Moderna NASDAQ:MRNA

$54.07 -2.95 (-5.17%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$54.14 +0.07 (+0.13%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$35.01 -0.09 (-0.26%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$35.82 +0.81 (+2.31%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.